GRAIL to Present at TD Cowen 45th annual Health Care Conference

MENLO PARK, Calif. – GRAIL, Inc. (Nasdaq: GRAL), a leading healthcare company dedicated to early cancer detection, announced today that its management team will participate in the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, March 4th at 9:10 a.m. ET.

Investors and interested parties can access the live and replay webcasts through the investor relations section of GRAIL’s website at investors.grail.com.The webcast will be archived for at least 30 days following the event.

About GRAIL

GRAIL’s mission is to revolutionize cancer detection and treatment by enabling early diagnosis when the disease is most treatable. Leveraging the power of next-generation sequencing, extensive population-scale clinical studies, and sophisticated machine learning, software, and automation, GRAIL aims to detect and identify multiple types of deadly cancers in their earliest stages.

The company’s targeted methylation-based platform holds important potential for various aspects of cancer care, including screening and precision oncology. This platform can contribute to multi-cancer early detection in symptomatic patients,risk stratification,minimal residual disease detection,biomarker subtyping,treatment and recurrence monitoring,ultimately enhancing the continuum of cancer care.

Headquartered in Menlo Park, California, GRAIL also has offices in Washington, D.C., North Carolina, and the United Kingdom. For further facts about GRAIL’s groundbreaking work, visit grail.com.

This approach to early cancer detection promises to considerably reduce the global burden of cancer by enabling timely interventions and improving patient outcomes. Through its innovative technologies and unwavering commitment to innovation, GRAIL is making strides towards a future where cancer is no longer a death sentence but a manageable disease.

How do you think early and comprehensive cancer detection will transform global cancer care in the next decade?

expert insights: A Conversation with GRAIL’s Dr. Alex Hart on the Future of Cancer Detection

Archyde News Interviews GRAIL’s Chief Scientific Officer as the Company Presents at TD Cowen’s 45th Annual Health Care Conference

Archyde News recently spoke with Dr.Alex Hart, Chief Scientific Officer at GRAIL, inc., about the company’s pioneering work in early cancer detection, their upcoming presentation at the TD Cowen 45th Annual Health Care Conference, and the broader implications of their technology on cancer care.

Archyde News: Dr. Hart, thank you for joining us today. Let’s dive right in. Can you tell our readers more about GRAIL’s mission and how your technology is revolutionizing cancer detection?

Dr. Alex Hart: Thank you for having me. GRAIL’s mission is to detect cancer early when it’s most treatable. We’re using next-generation sequencing and sophisticated machine learning to identify specific changes in circulating DNA that indicate the presence of cancer. our technology has the potential to detect multiple cancer types from a single blood draw, making it a game-changer for early detection.

Archyde News: That’s engaging. How does GRAIL’s approach differ from traditional screening methods?

Dr. Alex Hart: Traditional cancer screening methods often rely on symptoms or use imaging techniques like mammograms and colonoscopies.While these have benefits, they’re limited in their ability to detect many cancer types early. Our approach, using cell-free DNA in blood, allows us to screen for a wide range of cancers at the molecular level, which can lead to earlier detection and better outcomes.

Archyde News: GRAIL is presenting at the TD Cowen 45th Annual Health Care Conference. What can attendees expect to learn about your work?

Dr. Alex Hart: We’re excited to share updates on our multi-cancer early detection programme, Galleri. We’ll be discussing our large-scale clinical studies, like SUMMIT and Circle, and providing insights into how our proprietary technology is performing. We’ll also touch on our vision for how Galleri can fit into the broader cancer care continuum.

Archyde News: That’s sure to be an enlightening session. Looking ahead, what do you see as the greatest opportunities and challenges for your work?

Dr. Alex Hart: The opportunity is clear – to save lives by detecting cancer earlier. The challenge is ensuring our technology is accessible and used effectively at a global scale. We’re working hard to validate our approach in diverse populations, develop user-friendly interfaces, and build partnerships with healthcare systems to make our test widely available.

Archyde News: A fascinating and critical mission. Now, a thought-provoking question for our readers: How do you think early and comprehensive cancer detection will transform global cancer care in the next decade?

Dr. Alex Hart: I believe we’ll see a significant shift towards prevention and early intervention. with more accurate, early detection tools like Galleri, we can catch cancers sooner, reduce mortality rates, and ultimately make cancer a manageable disease. I’m optimistic about progress in the next decade, especially as we continue to validate and refine our technology.

Learn more about GRAIL’s groundbreaking work in early cancer detection

Disclaimer: This interview has been conducted in a simulated context to this demonstration and does not reflect an actual conversation or event. The views expressed here are fictional and not attributable to any real person or organization.